Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation
Following allogeneic blood and marrow transplantation (BMT), graft-versus-host disease (GvHD) continues to represent a significant cause of treatment failure, despite the routine use of conventional, mainly calcineurin inhibitor-based prophylaxis. Recently, post-transplant cyclophosphamide (PTCy) ha...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00636/full |
| _version_ | 1830509903414820864 |
|---|---|
| author | Louis Williams Frank Cirrone Kelli Cole Maher Abdul-Hay Leo Luznik Ahmad Samer Al-Homsi |
| author_facet | Louis Williams Frank Cirrone Kelli Cole Maher Abdul-Hay Leo Luznik Ahmad Samer Al-Homsi |
| author_sort | Louis Williams |
| collection | DOAJ |
| description | Following allogeneic blood and marrow transplantation (BMT), graft-versus-host disease (GvHD) continues to represent a significant cause of treatment failure, despite the routine use of conventional, mainly calcineurin inhibitor-based prophylaxis. Recently, post-transplant cyclophosphamide (PTCy) has emerged as a safe and efficacious alternative. First, omitting the need for ex vivo T-cell depletion in the setting of haploidentical transplantation, growing evidence supports PTCy role in GvHD prevention in matched-related and matched-unrelated transplants. Through improved understanding of GvHD pathophysiology and advancements in drug development, PTCy emerges as a unique opportunity to design calcineurin inhibitor-free strategies by integrating agents that target different stages of GvHD development. |
| first_indexed | 2024-12-22T01:42:42Z |
| format | Article |
| id | doaj.art-100d22a9d67d4ab8a0e8d3dc7b19b766 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T01:42:42Z |
| publishDate | 2020-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-100d22a9d67d4ab8a0e8d3dc7b19b7662022-12-21T18:43:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-04-011110.3389/fimmu.2020.00636536052Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow TransplantationLouis Williams0Frank Cirrone1Kelli Cole2Maher Abdul-Hay3Leo Luznik4Ahmad Samer Al-Homsi5Division of Hematology and Medical Oncology, NYU Langone Health, New York, NY, United StatesBlood and Marrow Transplantation Program, NYU Langone Health, New York, NY, United StatesBlood and Marrow Transplantation Program, NYU Langone Health, New York, NY, United StatesBlood and Marrow Transplantation Program, NYU Langone Health, New York, NY, United StatesDivision of Oncology, Johns Hopkins University, Baltimore, MD, United StatesBlood and Marrow Transplantation Program, NYU Langone Health, New York, NY, United StatesFollowing allogeneic blood and marrow transplantation (BMT), graft-versus-host disease (GvHD) continues to represent a significant cause of treatment failure, despite the routine use of conventional, mainly calcineurin inhibitor-based prophylaxis. Recently, post-transplant cyclophosphamide (PTCy) has emerged as a safe and efficacious alternative. First, omitting the need for ex vivo T-cell depletion in the setting of haploidentical transplantation, growing evidence supports PTCy role in GvHD prevention in matched-related and matched-unrelated transplants. Through improved understanding of GvHD pathophysiology and advancements in drug development, PTCy emerges as a unique opportunity to design calcineurin inhibitor-free strategies by integrating agents that target different stages of GvHD development.https://www.frontiersin.org/article/10.3389/fimmu.2020.00636/fullGvHD preventionpost-transplant cyclophosphamidematched-related donormatched unrelated donorbortezomibcalcineurin inhibitor-free |
| spellingShingle | Louis Williams Frank Cirrone Kelli Cole Maher Abdul-Hay Leo Luznik Ahmad Samer Al-Homsi Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation Frontiers in Immunology GvHD prevention post-transplant cyclophosphamide matched-related donor matched unrelated donor bortezomib calcineurin inhibitor-free |
| title | Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation |
| title_full | Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation |
| title_fullStr | Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation |
| title_full_unstemmed | Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation |
| title_short | Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation |
| title_sort | post transplantation cyclophosphamide from hla haploidentical to matched related and matched unrelated donor blood and marrow transplantation |
| topic | GvHD prevention post-transplant cyclophosphamide matched-related donor matched unrelated donor bortezomib calcineurin inhibitor-free |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2020.00636/full |
| work_keys_str_mv | AT louiswilliams posttransplantationcyclophosphamidefromhlahaploidenticaltomatchedrelatedandmatchedunrelateddonorbloodandmarrowtransplantation AT frankcirrone posttransplantationcyclophosphamidefromhlahaploidenticaltomatchedrelatedandmatchedunrelateddonorbloodandmarrowtransplantation AT kellicole posttransplantationcyclophosphamidefromhlahaploidenticaltomatchedrelatedandmatchedunrelateddonorbloodandmarrowtransplantation AT maherabdulhay posttransplantationcyclophosphamidefromhlahaploidenticaltomatchedrelatedandmatchedunrelateddonorbloodandmarrowtransplantation AT leoluznik posttransplantationcyclophosphamidefromhlahaploidenticaltomatchedrelatedandmatchedunrelateddonorbloodandmarrowtransplantation AT ahmadsameralhomsi posttransplantationcyclophosphamidefromhlahaploidenticaltomatchedrelatedandmatchedunrelateddonorbloodandmarrowtransplantation |